Key result
Clopidogrel-aspirin provided greater benefit than aspirin alone in patients with ischemic stroke or transient ischemic attack and a higher neutrophil count, without increasing bleeding risk.
Why the study?
Inflammation is an important mechanism in ischemic stroke and high-risk TIA, but clinical inflammatory markers on antiplatelet therapy remain to be studied.
Does clopidogrel-aspirin improve 90-day outcomes compared to aspirin alone in patients with ischemic stroke or TIA stratified by neutrophil count?
RCT
Double-blind
2-by-2 factorial
Yes
Does clopidogrel-aspirin improve 90-day outcomes compared to aspirin alone in patients with ischemic stroke or TIA stratified by neutrophil count?
In patients with ischemic stroke or TIA, a higher neutrophil count identifies a subgroup that derives greater benefit from dual antiplatelet therapy with clopidogrel and aspirin without increased bleeding risk.
Answers are grounded in this paper and cite their sources.
May support neutrophil-guided dual antiplatelet therapy after ischemic stroke or TIA; hypothesis-generating and requires randomized confirmation before practice change.
BACKGROUND: Inflammation is an important mechanism in ischemic stroke and high-risk transient ischemic attack, but clinical inflammatory markers on antiplatelet therapy remain to be studied. This study was designed compare the neutrophil count (NC) on the efficacy and safety of clopidogrel-aspirin with that of aspirin in patients with ischemic stroke or high-risk transient ischemic attack caused by intracranial or extracranial atherosclerosis. METHODS: The INSPIRES (Intensive Statin and Antiplatelet Therapy for High-Risk Intracranial or Extracranial Atherosclerosis) study was a post hoc analysis of the multicenter, randomized, double-blind, placebo-controlled, 2-by-2 factorial trial. The primary efficacy and safety outcomes were 90-day stroke and moderate-to-severe bleeding. The differences in the efficacy outcome were calculated with cox proportional hazards model and the generalized linear model as well as logistic regression. RESULTS: /L). Patients with ischemic stroke or transient ischemic attack with a higher NC benefited more from clopidogrel-aspirin than from aspirin alone. There was no significant difference in the primary safety outcome of moderate-to-severe bleeding according to antiplatelet therapy or NC. CONCLUSIONS: The post hoc analysis suggested patients with a higher NC obtained greater benefit from clopidogrel-aspirin than from aspirin without an increase in bleeding risk. The findings may serve as a reference indicator for future anti-inflammatory therapy. However, further research is needed to explore the mechanism.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2025) conducted an RCT in Ischemic stroke or high-risk transient ischemic attack. Clopidogrel-aspirin vs. Aspirin was evaluated on 90-day stroke and moderate-to-severe bleeding. Clopidogrel-aspirin provided greater benefit than aspirin alone in patients with ischemic stroke or transient ischemic attack and a higher neutrophil count, without increasing bleeding risk.
Synapse has enriched 10 related papers. Consider them for comparative context: